A study of biochemical markers of reperfusion early after thrombolysis for acute myocardial infarction. The PERM Study Group. Prospective Evaluation of Reperfusion Markers.
BACKGROUND
In acute myocardial infarction (AMI), early noninvasive identification of patients with occluded infarct-related arteries (IRAs) after thrombolysis has important prognostic and therapeutic implications. The aims of this study were to evaluate biochemical methods for the early diagnosis of patency after thrombolysis prospectively and to establish the optimal diagnostic criteria retrospectively.


RESULTS
In 97 patients with AMI treated with thrombolytic agents < or = 6 hours after the onset of symptoms, myoglobin, troponin T, creatine kinase, the MB isoenzyme and MM isoforms of creatine kinase were measured just before thrombolysis began and 90 minutes later. IRA patency was assessed by means of 90-minute coronary angiography. For each marker, compared with the expected sensitivity and specificity based on published thresholds for the diagnosis of patency, the observed values were consistently lower but were markedly improved in a subset of patients treated > 3 hours after the onset of symptoms. With receiver-operator characteristic curve analysis of the slopes of increase and relative increases in each marker over 90 minutes, the best diagnostic performance was achieved by use of the relative increase in myoglobin, troponin T, and MM3/MM1 creatine kinase isoforms in patients treated > 3 hours after onset (areas under the curve of 0.84, 0.83, and 0.85, respectively).


CONCLUSIONS
Effective early noninvasive diagnosis of patency after thrombolysis is possible in patients treated > 3 hours after symptom onset by use of criteria derived from the relative increase over 90 minutes in plasma markers, particularly myoglobin, troponin T, and MM3/MM1 creatine kinase isoforms. The diagnostic performance of the relative increase in myoglobin appears to be less susceptible to small changes in the diagnostic threshold value.
Laperche
T
T
Cardiology Department, Hôpital Beaujon, Clichy, France.
Steg
P G
PG
Dehoux
M
M
Benessiano
J
J
Grollier
G
G
Aliot
E
E
Mossard
J M
JM
Aubry
P
P
Coisne
D
D
Hanssen
M
M
D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D015331:Cohort Studies; D017023:Coronary Angiography; D003331:Coronary Vessels / Q000503:physiopathology; D003402:Creatine Kinase / Q000097:blood; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D007527:Isoenzymes; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy*; D015425:Myocardial Reperfusion; D009211:Myoglobin / Q000097:blood; D011237:Predictive Value of Tests; D012372:ROC Curve; D012680:Sensitivity and Specificity; D015912:Thrombolytic Therapy; D014336:Troponin / Q000097:blood; D020107:Troponin T; D014654:Vascular Patency / Q000502:physiology
D015415:Biomarkers; D005343:Fibrinolytic Agents; D007527:Isoenzymes; D009211:Myoglobin; D014336:Troponin; D020107:Troponin T; D003402:Creatine Kinase